Influence of microemulsion components on transdermal delivery of immunomodulator glucosaminylmuramyl dipeptide

This paper demonstrates a chemical way of enhancing transdermal delivery using immunomodulator glucosaminylmuramyl dipeptide (GMDP) as an example. Objective: to study in vitro the effect of various components of the microemulsion composition on GMDP diffusion through the skin from a transdermal therapeutic system (TTS). Materials and methods. Medicinal substance – glucosaminylmuramyl dipeptide (Peptek, Russia). Excipients and raw materials: sodium chloride, purified water, sodium dodecyl sulfate, docusate sodium, oak bark, apricot kernel oil, alpha-tocopheryl acetate and Decaglyn PR-20 emulsifier. Equipment: Heidolph DIAX 900 mechanical disperser (Germany) and Hielscher UIS250V ultrasonic homogenizer (Germany). GMDP diffusion from TTS through unpreserved rabbit skin was studied on diffusion tester Copley (UK). GMDP in aqueous solutions was determined by reversed-phase high-performance liquid chromatography (RP-HPLC) on an Agilent 1200 chromatography system (Agilent Technologies, USA). Results. A microemulsion system composed of 20% docusate sodium in an oil phase and an oak bark decoction as an aqueous phase was developed. This made it possible to increase GMDP transdermal delivery by ~70% in comparison with the basic composition. Conclusion. The characteristic parameters of microemulsion components of GMDP contained in TTS, influencing GMDP diffusion through unpreserved rabbit skin in vitro, were determined. Introducing relative indicators would be advisable in order to correctly evaluate the results of different series of in vitro experiments with biological objects.

1. Marwah H, Garg T, Goyal AK, Rath G. Permeation enhancer strategies in transdermal drug delivery. Journal Drug Delivery. 2016; 23: 564–578. doi: 10.3109/10717544.2014.935532.

2. Huzill JT, Sivaloganathan S, Kohandel M, Foldvari M. Drug delivery through the skin: molecular simulations of barrier lipids to design more effective noninvasive dermal and transdermal delivery systems for small molecules, biologics, and cosmetics. www.wiley.com/wires/nanomed.

3. Otto A, du Plessis J, Wiechers JW. Formulation effects of topical emulsions on transdermal and dermal delivery. International Journal Cosmetic Science. 2009; 31 (1): 1–19. doi: 10.1111/j.1468-2494.2008.00467.x.

4. Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Advances in Colloid and Interface Science. 2006; 123–126: 369–385. doi: 10.1016/j.cis.2006.05.014.

5. Azeem A, Khan ZI, Aqil M, Ahmad FJ, Khar RK, Talegaonkar S. Microemulsions as a surrogate carrier for dermal drug delivery. Drug Development and Industrial Pharmacy. 2009; 35 (5): 525–547. doi: 10.1080/03639040802448646.

6. Lopes LB. Overcoming the cutaneous barrier with microemulsions. Pharmaceutics. 2014; 6 (1): 52–77. doi: 10.3390/pharmaceutics6010052.

7. Heuschkel S, Goebel A, Neubert RH. Microemulsions – modern colloidal carrier for dermal and transdermal drug delivery. Journal of Pharmaceutical Sciences. 2008; 97 (2): 603–631. doi.org/10.1002/jps.20995.

8. Kuznetsova EG, Kuryleva OM, Salomatina LA, Sevastyanov VI. Eksperimental’noe issledovanie diffuzii immunomodulyatora Galavit ® v model’noj sisteme. Razrabotka i registraciya lekarstvennyh sredstv. 2020; 9 (1): 92–97. doi: 10.33380/2305-2066-2020-9-1-92-97. (in Russ., English abstract).

9. Ryzhikova VA, Tikhobayeva AA, Salomatina LA, Kursakov SV, Kuznetsova EG, Kuryleva OM, Sevastyanov VI. Effect of the transfer activator on functional properties of the bromocain matrix transdermal therapeutic systems. Inorganic Materials: applied research. 2014: 5 (5): 498–503. doi: 10.1134/s2075113314050177.

10. Kuznetsova EG, Ryzhikova VA, Salomatina LA, Sevastyanov VI. Issledovanie harakteristicheskih parametrov mikroemul’sionnoj kompozicii dlya transdermal’noj dostavki insulina. Razrabotka i registracija lekarstvennyh sredstv. 2017; 2: 66–72. (In Russ., English abstract).

11. Date AA, Patravale VB. Microemulsions: applications in transdermal and dermal delivery. Critical Reviews in Therapeutic Drug Carrier Systems. 2007; 24 (6): 547–596. doi: 10.1615/critrevtherdrugcarriersyst.v24.i6.20

12. Kursakov SV, Kuznetsova EG, Kuryleva OM, Salomatina LA, Gurjanova SV, Borisova OJu I dr. Razrabotka i validaciya metodiki opredeleniya glyukozaminilmuramildipeptida v vodnyh rastvorah metodom vysokoeffektivnoj zhidkostnoj hromatografii. Immunologija. 2020, 41 (1): 74–82. doi: 10.33029/0206-4952-2020-41-1-74-82. (In Russ., English abstract).

13. Gosudarstvennyj reestr lekarstvennyh sredstv 2020 g. (In Russ.).

14. Haitov RM, Pinegin BV, Andronova TM. Otechestvennye immunotropnye lekarstvennye sredstva poslednego pokoleniya i strategiya ih primeneniya. Lechashhij vrach. 1998; 4: 46–51. (In Russ.).

15. Shepel’ VS. O sostavlenii smesej rastitel’nyh masel dlya kosmeticheskih kompozicij [Elektronnyy resurs] – http://www.tusheflora.ru/review/publications/2010/o_sostavlenii_smesej_rastitelnih_masel_dlya_kosmeticheskih_kompozitcij/, svobodnyy. (In Russ.).

16. Bykova SF, Davidenko EK, Efimenko SG. Perspektivy razvitiya syr’evoj bazy proizvodstva novyh tipov pishchevyh rastitel’nyh masel. Masla i zhiry. 2014; 1: 20–25. (In Russ.).

17. Hohlenkova NV. Razrabotka promyshlennoj tekhnologii salfetok s gustym ekstraktom kory duba i natriya al’ginatom Vestnik farmacii. 2013; 2 (60): 40–47 (In Russ.).